ArticleEuropean journal of pediatrics2026
Serum IL-6, IL-8, and Th/Ts ratio for severity assessment and short-term clinical outcome risk stratification in pediatric Mycoplasma pneumoniae pneumonia: insights into inflammation-immune imbalance.
Article in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycoplasma pneumoniae pneumonia (MPP) exhibits significant clinical heterogeneity in children. This study investigated the clinical utility of serum interleukin-6 (IL-6), interleukin-8 (IL-8), and the T helper/T suppressor (Th/Ts) cell ratio for evaluating disease severity and 1-month short-term clinical outcomes in pediatric MPP. We retrospectively enrolled 194 hospitalized children with MPP without co-infection (102 mild, 92 severe; 171 favorable short-term clinical outcome, 23 poor short-term clinical outcome). Core biomarker levels were compared between groups. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curves. Bootstrap mediation analysis was used to explore the statistical association pathway between systemic inflammation and cellular immune status. For short-term outcome risk stratification, LASSO logistic regression was performed as a sensitivity analysis, and candidate prognostic models were compared. Patients with severe MPP and poor short-term clinical outcomes exhibited significantly elevated IL-6 and IL-8 levels and a reduced Th/Ts ratio (all P < 0.001). A combined diagnostic model incorporating these three biomarkers achieved an AUC of 0.943 for predicting severe MPP. Mediation analysis suggested that the Th/Ts ratio partially mediated the associations of IL-6 (30.3%) and IL-8 (19.2%) with disease severity. For short-term outcome risk stratification, a parsimonious exploratory nomogram incorporating lactate dehydrogenase (LDH), IL-6, and the Th/Ts ratio showed favorable internal performance (C-index = 0.89), calibration, and clinical net benefit.Conclusions: Pediatric MPP is characterized by an inflammation-immune imbalance pattern involving elevated IL-6 and IL-8 levels and a reduced Th/Ts ratio. The LDH, IL-6, and Th/Ts ratio-based nomogram may serve as an exploratory risk-stratification tool for 1-month short-term clinical outcomes, but external validation in multicenter prospective cohorts is required before routine clinical application.
Indexed as
Identifiers
42417864What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.